RU2019116624A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019116624A3 RU2019116624A3 RU2019116624A RU2019116624A RU2019116624A3 RU 2019116624 A3 RU2019116624 A3 RU 2019116624A3 RU 2019116624 A RU2019116624 A RU 2019116624A RU 2019116624 A RU2019116624 A RU 2019116624A RU 2019116624 A3 RU2019116624 A3 RU 2019116624A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619648.7A GB201619648D0 (en) | 2016-11-21 | 2016-11-21 | Novel antibodies and uses thereof |
| GB1619648.7 | 2016-11-21 | ||
| PCT/EP2017/079930 WO2018091740A2 (en) | 2016-11-21 | 2017-11-21 | Novel antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019116624A RU2019116624A (ru) | 2020-12-21 |
| RU2019116624A3 true RU2019116624A3 (enExample) | 2021-01-29 |
Family
ID=57993708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019116624A RU2019116624A (ru) | 2016-11-21 | 2017-11-21 | Новые анти_cd137 антитела и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11535678B2 (enExample) |
| EP (1) | EP3541844A2 (enExample) |
| JP (1) | JP7068303B2 (enExample) |
| KR (1) | KR102679632B1 (enExample) |
| CN (1) | CN109963873B (enExample) |
| AU (1) | AU2017360094B2 (enExample) |
| BR (1) | BR112019010265A2 (enExample) |
| CA (1) | CA3044339A1 (enExample) |
| GB (1) | GB201619648D0 (enExample) |
| IL (1) | IL266738B2 (enExample) |
| MX (1) | MX2019005911A (enExample) |
| NZ (1) | NZ754051A (enExample) |
| RU (1) | RU2019116624A (enExample) |
| WO (1) | WO2018091740A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017220555A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Lag -3 binding members |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| TWI842672B (zh) | 2017-04-13 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｃｄ１３７抗體及其使用方法 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| JOP20200016B1 (ar) * | 2017-08-01 | 2022-10-30 | Lilly Co Eli | أجسام مضادة لـ cd137 |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| AU2019239194B2 (en) | 2018-03-23 | 2023-09-14 | Eli Lilly And Company | Anti-CD137 antibodies for combination with anti-PD-L1 antibodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| CA3106046A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind pd-l1 and cd137 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| WO2020023556A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy |
| SG10202106830VA (en) * | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| EP3850012A4 (en) * | 2018-09-12 | 2022-06-15 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-TNFRSF9 ANTIBODIES AND THEIR USES |
| CA3125451A1 (en) * | 2019-01-02 | 2020-07-09 | Qlsf Biotherapeutics Inc. | Cd137 agonist antibodies and uses thereof |
| KR20220003572A (ko) | 2019-04-24 | 2022-01-10 | 하이델베르크 파마 리서치 게엠베하 | 아마톡신 항체-약물 결합체 및 이의 용도 |
| AU2020308463A1 (en) | 2019-06-26 | 2022-02-17 | Ap Biosciences, Inc. | Antibodies for T-cell activation |
| US20220411523A1 (en) * | 2019-11-13 | 2022-12-29 | Hefei Hankemab Biotechnology Co., Ltd | Molecule capable of binding to human 4-1bb and its application thereof |
| MX2022008412A (es) | 2020-01-07 | 2022-08-08 | Univ Texas | Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer. |
| CN115066440A (zh) * | 2020-02-28 | 2022-09-16 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
| EP4153316A1 (en) | 2020-05-19 | 2023-03-29 | Boehringer Ingelheim International GmbH | Binding molecules for the treatment of cancer |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| EP4155319A4 (en) * | 2020-06-30 | 2024-06-12 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1BB BINDING PROTEIN AND ITS USE |
| KR20230129484A (ko) * | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 4-1bb와 특이적으로 결합하는 항체 및 그 항원 결합단편 |
| JP2024522234A (ja) | 2021-06-18 | 2024-06-11 | アリゲーター・バイオサイエンス・アーベー | 新規な併用療法及びその使用 |
| GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025531938A (ja) * | 2022-09-22 | 2025-09-25 | アブリンク バイオテック カンパニー リミテッド | 抗４－１ｂｂナノボディ、その製造及び使用 |
| CN116041517B (zh) * | 2022-12-19 | 2025-02-25 | 首都医科大学附属北京胸科医院 | 一种抗人cd137抗体及其应用 |
| CN116162162B (zh) * | 2022-12-19 | 2025-05-27 | 首都医科大学附属北京胸科医院 | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 |
| CN116271009A (zh) * | 2023-01-13 | 2023-06-23 | 深圳市乐土生物医药有限公司 | 含有CpG佐剂和4-1BB抗体的药物组合物及其用途 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| TWI423814B (zh) | 2006-09-01 | 2014-01-21 | Genticel | 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子 |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| JP2018508509A (ja) * | 2015-02-22 | 2018-03-29 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ１３７に結合する抗体医薬 |
| EP3988577A1 (en) * | 2015-05-21 | 2022-04-27 | Alligator Bioscience AB | Anti-cd137 antibodies |
-
2016
- 2016-11-21 GB GBGB1619648.7A patent/GB201619648D0/en not_active Ceased
-
2017
- 2017-11-21 MX MX2019005911A patent/MX2019005911A/es unknown
- 2017-11-21 US US16/461,544 patent/US11535678B2/en active Active
- 2017-11-21 NZ NZ754051A patent/NZ754051A/en unknown
- 2017-11-21 EP EP17811475.7A patent/EP3541844A2/en active Pending
- 2017-11-21 CN CN201780071444.6A patent/CN109963873B/zh active Active
- 2017-11-21 KR KR1020197015905A patent/KR102679632B1/ko active Active
- 2017-11-21 WO PCT/EP2017/079930 patent/WO2018091740A2/en not_active Ceased
- 2017-11-21 IL IL266738A patent/IL266738B2/en unknown
- 2017-11-21 RU RU2019116624A patent/RU2019116624A/ru unknown
- 2017-11-21 JP JP2019527232A patent/JP7068303B2/ja active Active
- 2017-11-21 AU AU2017360094A patent/AU2017360094B2/en active Active
- 2017-11-21 CA CA3044339A patent/CA3044339A1/en active Pending
- 2017-11-21 BR BR112019010265A patent/BR112019010265A2/pt unknown
-
2019
- 2019-07-17 US US16/514,374 patent/US10689454B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109963873B (zh) | 2023-12-26 |
| RU2019116624A (ru) | 2020-12-21 |
| CN109963873A (zh) | 2019-07-02 |
| US20190352414A1 (en) | 2019-11-21 |
| CA3044339A1 (en) | 2018-05-24 |
| US20190352411A1 (en) | 2019-11-21 |
| US10689454B2 (en) | 2020-06-23 |
| US20230295325A1 (en) | 2023-09-21 |
| WO2018091740A3 (en) | 2018-06-28 |
| IL266738B1 (en) | 2024-02-01 |
| BR112019010265A2 (pt) | 2019-09-17 |
| KR102679632B1 (ko) | 2024-06-28 |
| IL266738A (en) | 2019-07-31 |
| JP2020501531A (ja) | 2020-01-23 |
| MX2019005911A (es) | 2019-07-08 |
| NZ754051A (en) | 2023-05-26 |
| EP3541844A2 (en) | 2019-09-25 |
| AU2017360094A1 (en) | 2019-06-20 |
| JP7068303B2 (ja) | 2022-05-16 |
| GB201619648D0 (en) | 2017-01-04 |
| KR20190086691A (ko) | 2019-07-23 |
| AU2017360094B2 (en) | 2024-12-12 |
| US11535678B2 (en) | 2022-12-27 |
| IL266738B2 (en) | 2024-06-01 |
| WO2018091740A2 (en) | 2018-05-24 |